URG; Beta-Urogastrone; Pro-epidermal growth factor
- FOB US$ 349.00 US$ 498.00 US$ 2,241.00 US$ 4,233.00 US$ 34,860.00
- Quantity In stock
- Product No.SEA560Mu
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- ApplicationsEnzyme-linked immunosorbent assay for Antigen Detection.
Research use only
- DownloadInstruction Manual
- CategoryCytokineTumor immunityInfection immunity
- Test MethodDouble-antibody Sandwich
- Assay Length3h
- Detection Range7.8-500pg/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 2.9pg/mL.
- Specificity This assay has high sensitivity and excellent specificity for detection of Epidermal Growth Factor (EGF).No significant cross-reactivity or interference between Epidermal Growth Factor (EGF) and analogues was observed.
Sign into your account
Share a new citation as an author
Upload your experimental result
Please fill in the blank.
- Packages (Simulation)
- Packages (Simulation)
- Results demonstration
- Typical Standard Curve
- ISO9001: 2008, ISO13485: 2003 Registered
Matrices listed below were spiked with certain level of recombinant Epidermal Growth Factor (EGF) and the recovery rates were calculated by comparing the measured value to the expected amount of Epidermal Growth Factor (EGF) in samples.
|Matrix||Recovery range (%)||Average(%)|
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Epidermal Growth Factor (EGF) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Epidermal Growth Factor (EGF) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Epidermal Growth Factor (EGF) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
|Pre-coated, ready to use 96-well strip plate||1||Plate sealer for 96 wells||4|
|Detection Reagent A||1×120µL||Assay Diluent A||1×12mL|
|Detection Reagent B||1×120µL||Assay Diluent B||1×12mL|
|TMB Substrate||1×9mL||Stop Solution||1×6mL|
|Wash Buffer (30 × concentrate)||1×20mL||Instruction manual||1|
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.
The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Epidermal Growth Factor (EGF). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Epidermal Growth Factor (EGF). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Epidermal Growth Factor (EGF), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Epidermal Growth Factor (EGF) in the samples is then determined by comparing the O.D. of the samples to the standard curve.
- The influence of nutrients, biliary-pancreatic secretions, and systemic trophic hormones on intestinal adaptation in a Roux-en-Y bypass modelPubMed: 20438940
- Decreased Epidermal Growth Factor (EGF) Associated with HMGB1 and Increased Hyperactivity in Children with AutismPubMed: PMC3623607
- The Probiotic Mixture VSL#3 Accelerates Gastric Ulcer Healing by Stimulating Vascular Endothelial Growth FactorPubMed: PMC3590171
- Allogeneic transplantation of an adipose-derived stem cell (ASC) sheet combined with artificial skin accelerates wound healing in a rat wound model of type 2 diabetes and obesityPubmed:25795216
- Association of colon adenomas and skin tags: coincidence or coexistence?Pubmed:24763889
- The effects of self-assembling peptide RADA16 hydrogel on malignant phenotype of human hepatocellular carcinoma cellPubMed: 26628972
- Polydopamine nanoparticles modulating stimuli-responsive PNIPAM hydrogels with cell/tissue adhesiveness.pubmed:27709887
- The effect of midkine on growth factors and oxidative status in an experimental wound model in diabetic and healthy ratspubmed:28177680